TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 20, 2023 in Y-mAbs Lawsuit - YMAB

Newsfile 25-Jan-2023 4:28 PM

New York, New York--(Newsfile Corp. - January 25, 2023) - Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ:YMAB) of a class action securities lawsuit.

The lawsuit on behalf of Y-mAbs investors has been commenced in the the United States District Court for the Southern District of New York. This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35942&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/152507_227391_logo.jpg

Y-mAbs Therapeutics, Inc. NEWS - YMAB NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ("FDA") willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Y-mAbs during the relevant timeframe, you have until March 20, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35942&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/152507

Image for Press Release 1627327